Fig. 2.
Use of therapeutic or preventive treatments for bone-marrow suppression (n = 1465). (A) After start of radium-223 treatment in patients who did or did not receive prior chemotherapy. (B) After completion of radium-223 treatment in patients who did or did not receive subsequent chemotherapy. aPatients may have received chemotherapy at other times.